Two cases of torsades de pointes caused by sotalol therapy

Resuscitation

Volumn 40, Issue 1, 1999, Pages 49-51

  Cammu, G ^a   Geelen, P ^a   Baetens, P ^a   De Vos, J ^a   Demeyer, I ^a  

^a OLV HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

SOTALOL;

AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; CASE REPORT; DEFIBRILLATION; DRUG ELIMINATION; DRUG MECHANISM; FEMALE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE FIBRILLATION; HEMODIALYSIS; HUMAN; HYPOKALEMIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TORSADE DES POINTES;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; SOTALOL; TORSADES DE POINTES;

EID: 0032997809     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9572(98)00146-4     Document Type: Article

References (15)

1. Hohnloser S.H. Proarrhythmia with class III antiarrhythmic drugs: types, risks and management. Am. J. Cardiol. 80(8A):1997;G82-G89.
2. Advani S.V., Singh B.N. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of D-sotalol, the dextro-isomer of sotalol. Drugs. 49(5):1995;664-679.
3. Funck-Brentano C. Pharmacokinetic and pharmacodynamic profiles of D-sotalol and D,L-sotalol. Eur. Heart J. 14:1993;30-35.
4. MacNeil D.J. The side effect profile of class III antiarrhythmic drugs: focus on D,L-sotalol. Am. J. Cardiol. 80(8A):1997;90G-98.
5. Kowey P.R, Marinchak R.A., Rials S.J., Bharucha D. Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs. Am. J. Cardiol. 80(8A):1997;16G-23G.
6. Lazzara R. Antiarrhythmic drugs and torsade de pointes. Eur. Heart J. 14:1993;88-92.
7. Hohnloser S.H., Woosley R.L., Sotalol N. Engl. J. Med. 331(1):1994;31-38.
8. Nair L.A., Grant A.O. Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential. Cardiovasc. Drugs Ther. 11(2):1997;149-167.
9. Kuhlkamp V., Mermi J., Mewis C., Seipel L. Efficacy and proarrhythmia with the use of D,L-sotalol for sustained ventricular tachyarrhythmias. J. Cardiovasc. Pharmacol. 29(3):1997;373-381.
10. Lehmann M.H., Hardy S., Archibald D., Quart B., MacNeil D.J. Sex difference in risk of torsade de pointes with D,L-sotalol. Circulation. 94(10):1996;2535-2541.
11. Basta M.N., Leitch J.W., Fletcher P.J. Sotalol proarrhythmia: a report of five cases and an audit of the use of sotalol in a teaching hospital. Aust. N. Z. J. Med. 26(2):1996;167-170.
12. Dancey D., Wulffhart Z., McEwan P. Sotalol-induced torsades de pointes in patients with renal failure. Can. J. Cardiol. 13(1):1997;55-58.
13. Singh S.N., Lazin A., Cohen A. et al. Sotalol induced torsades de pointes successfully treated with hemodialysis after failure of conventional therapy. Am. Heart J. 121(2):1991;601-602.
14. Faber T.S., Zehender M., Van de Loo A. et al. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports. Clin. Cardiol. 17(4):1994;197-202.
15. Feroze H., Suri R., Silverman D.I. Torsades de pointes from terfenadine and sotalol given in combination. Pacing Clin. Electrophysiol. 19(10):1996;1519-1521.